Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-21
2011-06-21
Habte, Kahsay T (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S219000, C514S221000
Reexamination Certificate
active
07964591
ABSTRACT:
Methods of treating an SCD-mediated skin disorder or condition in a mammal, preferably a human include administering to a mammal in need thereof a compound of formula (I):where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9and R9aare defined herein.
REFERENCES:
patent: 7514436 (2009-04-01), Gschwend et al.
patent: 7754711 (2010-07-01), Chakka et al.
patent: 2006/0205713 (2006-09-01), Gschwend et al.
patent: 10-007572 (1998-01-01), None
patent: 2000-508307 (2000-07-01), None
patent: 2002-012587 (2002-01-01), None
patent: 2007-500715 (2007-01-01), None
patent: 0210154 (2002-02-01), None
patent: 02/094799 (2002-11-01), None
English translation of a 2nd Office Action dated Jun. 25, 2010, from the Taiwan Patent Office in related Taiwan Patent Application No. 093122736 (2 pages).
English translation of an Examination Report (Office Action) dated Aug. 4, 2010, in related Chilean Patent Application No. 1930-2004 (3 pages).
Official Action issued Sep. 7, 2010, by the Japan Patent Office in related Japan Patent Application No. JP-2006-522075 (together with a transmittal letter and English translation indicating the references cited in the Official Action).
EPO Communication (Office Action) issued Aug. 23, 2010, by the Euorpean Patent Office in related European Application No. EP-04779562.0 (3 pages).
Examination Report dated Aug. 7, 2010, of the Patent Office of The Cooperation Council For The Arab States of The Gulf in related Patent Application No. GCC/P/2006/5793 (4 pages).
PCT International Preliminary Report on Patentability (IPRP) dated Sep. 10, 2010, from the International Bureau in related International Application No. PCT/IB2009/005350 (9 pages).
2nd Official Action mailed Nov. 15, 2010, by the Chilean Patent Office in related Chilean Patent Application No. 280-2006 (5 pages).
Office Action issued Sep. 16, 2010, by the Israeli Patent Office in related Israeli Application No. 173395 (4 pages).
Examination Report issued Dec. 7, 2010, by the Australian Patent Office in related Australian Patent Application No. 2009201788 (2 pages).
Official Action issued Feb. 1, 2011, by the Japan Patent Office in related Japanese Patent Application No. JP 2007-555182, with partial English translation (8 pages).
Final Rejection (Office Action) issued Feb. 22, 2011, by the Japan Patent Office in related Japanese Patent Application No. JP2006-522075, with English translation (3 pages).
Office Action issued Jan. 11, 2011, by the China Patent Office in related Chinese Patent Application No. CN2009-10173472.6, with English translation (9 pages).
Extended European Search Report dated Mar. 24, 2011, from the European Patent Office in corresponding European Patent Application No. 10184939.6 (5 pages).
Epo Communication (Office Action) dated Mar. 23, 2011, from the European Patent Office in related European Patent Application No. Ep-06748193.7 (4 pages).
Office Action issued Mar. 4, 2011, by the Taiwan Patent Office in related Taiwanese Patent Application No. TW-099123173 (partial English translation only) (3 pages).
Translation of Examination report issued Apr. 3, 2011, by the Ecuador Patent Office in related Ecuadorean Patent Application No. SP-06-6313 (2 pages).
Official Action issued Mar. 1, 2011, by the Norwegian Industrial Property Office in related Norwegian Patent Application No. 20060981, with English translation (15 pages).
Billich Andreas
Goldberg Yigal Paul
Winther Michael D.
Habte Kahsay T
Novartis Pharma AG
Osha • Liang LLP
Xenon Pharmaceuticals Inc.
LandOfFree
Pyridazine derivatives and their use as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridazine derivatives and their use as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridazine derivatives and their use as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2662554